Roberto G. Carassa, MD
Milano, Italy |
Combigan™ Overview and Neuroprotection, The New Approach on Glaucoma
Volume 36, Number # 1, 2008 Series
Roberto G. Carassa, MD
Milano, Italy |
1. European Glaucoma Society. Terminology and guidelines for glaucoma, 2nd edition. 2003. Available on-line at http://www.eugs.org/preview.asp
2. Heijl AH, Leske CM, Bengtsson B, Human L, Bengtsson B, Hussein M: Reduction of intraocular pressure and glaucoma progression. Results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-1279
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.
4. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–8.
5. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233–6.
6. Serle JB, Toor A, Fahim MM, et al. The effect of varying dosing interval on the efficacy of intraocular pressure lowering drugs. Invest Ophthalmol Vis Sci. 2004;45:ARVO e-abstract 974
7. Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333–8.
8. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556–63.
9. Schwartz GF: Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005;16:114-121
10. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–8.
11. Olthoff CM, Schouten JS, van de Borne BW, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953–61.
12. Konstas AG, Maskaleris G, Gratsonidis S, et al. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14 Pt 5:752–6.
13. Buller AJ, Morgan LH, Hercules BL. Patients prefer once-daily glaucoma drops. Graefes Arch Clin Exp Ophthalmol. 2006:Epub ahead of print.
14. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–3.
15. Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138–61.
16. Gobbels M, Spitznas M. Influence of artificial tears on corneal epithelium in dry-eye syndrome. Graefes Arch Clin Exp Ophthalmol. 1989;227:139–41.
17. Toris CB, Gleason ML, Camras CB, Yablonski ME: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-7.
18. Coakes RL, Brubacker RF: The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol 1978;96:2045-8.
19. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R, Combigan Group: Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337-48.
20. Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM: Twice-daily 0.2% brimonidine-0.5% timolol fixed combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8.
21. Konstas AG, Katsimpris IE, Kaltsos K, Georgiadou I, Kordelu A, Nelson LA, Stewart WC: Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye 2007;15: Epub ahead of print.
22. Goni FJ for the brimonidine/timolol fixed combination study group: 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90.
23. Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, Sa Filho WF: Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated ocular pressure. Curr Med Res Opin 2007; 23:683-9.
24. Wheeler L, WoldeMussie E, Lai R: Role of Alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48:S47-S51.
25. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-55.
26. Lafuente MP, Villegas-Perez MP, Sobrado-Calvo P et al.: Neuroprotective effects of alpha-2 adrenergic agonists against ischemia-mediated retinal ganglion cell death. Invest Ophthalmol Vis Sci 2001;42:2074-84.
27. Yoles E, Wheeler L, Schwartz M: Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999;40:65-73.
28. Burke J, Manlapaz C, Kharlamb A et al.: Therapeutic use of alpha-2 adrenceptor agonist in glaucoma. In Lanier SM, Limbird LE (eds): Alpha-adrenergic receptors structure, function and therapeutic implications. Reading, UK, Harwood Academic publishers, 1966, pp 179-87.
29. Kent A Nussdorf J, Fellows D, et al.: Brimonidine concentrations in the posterior segment of patients during Alphagan treatment. Ophthalmology 2001;108:784-7.
|
